September 26th 2022
Srdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.
September 14th 2022
Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.
May 4th 2022
Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.
May 3rd 2022
Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.
April 25th 2022
Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.
April 1st 2022
Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.
January 28th 2022
Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.
January 11th 2022
Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.
December 13th 2021
OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.
October 13th 2021
Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.
September 10th 2021
Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.
July 19th 2021
Srdan Verstovsek, MD, PhD, discusses the efficacy of the combination of pelabresib plus ruxolitinib in the treatment of patients with myelofibrosis.
June 17th 2021
Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.
May 21st 2021
Srdan Verstovsek, MD, PhD, discusses the rationale for utilizing ruxolitinib and navitoclax in patients with relapsed/refractory myelofibrosis.
May 18th 2021
Srdan Verstovsek, MD, PhD, discusses future research efforts for patients with myeloproliferative neoplasms.
May 10th 2021
Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.
May 3rd 2021
Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.
April 15th 2021
Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.
April 7th 2021
Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.
February 16th 2021
Srdan Verstovsek, MD, PhD, discusses the use of luspatercept to treat anemia associated with myelofibrosis.